Andrew’s 30-year career spans the biotech and financial services industries, with broad leadership expertise across strategy, finance, operations, investor relations and corporate development. He also brings significant capital markets and business development transaction experience. Prior to joining Vaxcyte in May 2020, he served as Chief Financial Officer of Dermira, Inc. through its acquisition by Eli Lilly and Company. During his tenure at Dermira, Andrew successfully led a series of private, public and alternative financings and helped scale the company, including through its initial public offering and pivotal transition into a commercial-stage organization. Previously, Andrew served as Chief Financial Officer at several fast-growing biotech companies, including Calistoga Pharmaceuticals, Inc., which was acquired by Gilead Sciences, Inc., and Facet Biotech Corporation, which was acquired by Abbott Laboratories.

Earlier in his career, Andrew served as Chief Financial Officer of PDL BioPharma, Inc. until Facet Biotech was spun off from PDL BioPharma. Prior to joining PDL BioPharma, he served as Chief Financial Officer of Neoforma, Inc., which was acquired by Global Healthcare Exchange, LLC. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company.

Andrew serves as the Board Chair of Caribou Biosciences, Inc. and is a member of the board of directors of Metacrine, Inc. He earned his BA in international politics and economics from Middlebury College and his MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

• 

  President in Vaxcyte

  Vaccine Innovation. Beyond Convention.

• 

  CFO: Chief Financial Officer in Vaxcyte

  Vaccine Innovation. Beyond Convention.